Kevin Bitterman - Net Worth and Insider Trading
Kevin Bitterman Net Worth
The estimated net worth of Kevin Bitterman is at least $96 Million dollars as of 2024-05-08. Kevin Bitterman is the Director of Akero Therapeutics Inc and owns about 2,523,075 shares of Akero Therapeutics Inc (AKRO) stock worth over $54 Million. Kevin Bitterman is the Director of Disc Medicine Inc and owns about 926,829 shares of Disc Medicine Inc (IRON) stock worth over $28 Million. Kevin Bitterman is also the Director of Editas Medicine Inc and owns about 2,797,144 shares of Editas Medicine Inc (EDIT) stock worth over $14 Million. Details can be seen in Kevin Bitterman's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kevin Bitterman has not made any transactions after 2024-03-05 and currently still holds the listed stock(s).
Transaction Summary of Kevin Bitterman
Kevin Bitterman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kevin Bitterman owns 5 companies in total, including Akero Therapeutics Inc (AKRO) , Editas Medicine Inc (EDIT) , and Genocea Biosciences Inc (GNCAQ) among others .
Click here to see the complete history of Kevin Bitterman’s form 4 insider trades.
Insider Ownership Summary of Kevin Bitterman
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AKRO | Akero Therapeutics Inc | 2020-10-09 | director |
| EDIT | Editas Medicine Inc | 2017-05-22 | director & 10 percent owner |
| GNCAQ | Genocea Biosciences Inc | 2015-02-26 | director |
 | | 2024-03-05 | director |
| | 2015-02-26 | director |
Kevin Bitterman Latest Holdings Summary
Kevin Bitterman currently owns a total of 3 stocks. Among these stocks, Kevin Bitterman owns 2,523,075 shares of Akero Therapeutics Inc (AKRO) as of October 9, 2020, with a value of $54 Million and a weighting of 56.46%. Kevin Bitterman owns 926,829 shares of Disc Medicine Inc (IRON) as of March 5, 2024, with a value of $28 Million and a weighting of 28.55%. Kevin Bitterman also owns 2,797,144 shares of Editas Medicine Inc (EDIT) as of May 22, 2017, with a value of $14 Million and a weighting of 14.99%.
Latest Holdings of Kevin Bitterman
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AKRO | Akero Therapeutics Inc | 2020-10-09 | 2,523,075 | 21.56 | 54,397,497 |
| IRON | Disc Medicine Inc | 2024-03-05 | 926,829 | 29.68 | 27,503,651 |
| EDIT | Editas Medicine Inc | 2017-05-22 | 2,797,144 | 5.17 | 14,447,249 |
Holding Weightings of Kevin Bitterman
Kevin Bitterman Form 4 Trading Tracker
According to the SEC Form 4 filings, Kevin Bitterman has made a total of 2 transactions in Akero Therapeutics Inc (AKRO) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Akero Therapeutics Inc is the sale of 13,000 shares on October 9, 2020, which brought Kevin Bitterman around $376,090.
According to the SEC Form 4 filings, Kevin Bitterman has made a total of 5 transactions in Disc Medicine Inc (IRON) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Disc Medicine Inc is the sale of 26,157 shares on March 5, 2024, which brought Kevin Bitterman around $2 Million.
According to the SEC Form 4 filings, Kevin Bitterman has made a total of 0 transactions in Editas Medicine Inc (EDIT) over the past 5 years. The most-recent trade in Editas Medicine Inc is the sale of 1,000,000 shares on May 22, 2017, which brought Kevin Bitterman around $17 Million.
Insider Trading History of Kevin Bitterman
- 1
Kevin Bitterman Trading Performance
GuruFocus tracks the stock performance after each of Kevin Bitterman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kevin Bitterman is 4.52%. GuruFocus also compares Kevin Bitterman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kevin Bitterman within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Kevin Bitterman's insider trading performs compared to the benchmark.
Performance of Kevin Bitterman
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 20.06 | | | | | |
| Relative Return to S&P 500(%) | 17.54 | | | | | |
Kevin Bitterman Ownership Network
Kevin Bitterman Owned Company Details
What does Akero Therapeutics Inc do?
Who are the key executives at Akero Therapeutics Inc?
Kevin Bitterman is the director of Akero Therapeutics Inc. Other key executives at Akero Therapeutics Inc include Chief Operating Officer Jonathan Young , director & President & CEO Andrew Cheng , and Chief Development Officer Catriona Yale .
Akero Therapeutics Inc (AKRO) Insider Trades Summary
Over the past 18 months, Kevin Bitterman made no insider transaction in Akero Therapeutics Inc (AKRO). Other recent insider transactions involving Akero Therapeutics Inc (AKRO) include a net sale of 343,870 shares made by Andrew Cheng , a net sale of 69,475 shares made by Jonathan Young , and a net sale of 82,268 shares made by Catriona Yale .
In summary, during the past 3 months, insiders sold 110,332 shares of Akero Therapeutics Inc (AKRO) in total and bought 0 shares, with a net sale of 110,332 shares. During the past 18 months, 2,373,568 shares of Akero Therapeutics Inc (AKRO) were sold and 1,320,000 shares were bought by its insiders, resulting in a net sale of 1,053,568 shares.
Akero Therapeutics Inc (AKRO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Akero Therapeutics Inc Insider Transactions
Kevin Bitterman Mailing Address
Above is the net worth, insider trading, and ownership report for Kevin Bitterman. You might contact Kevin Bitterman via mailing address: C/o Polaris Venture Partners, 1000 Winter Street, Suite 3350, Waltham Ma 02451.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
